ArticleMolecular oncology2017
FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.
Article in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Correlation of senescence-related gene FEN1 on neuroblastoma progression and cisplatin chemotherapy sensitivity.Oncology research · 2025Article
- Review
- Causal genetic regulation of DNA replication on immune microenvironment in colorectal tumorigenesis: Evidenced by an integrated approach of trans-omics and GWAS.Journal of biomedical research · 2023Article
- Article
- Inhibition of FEN1 promotes DNA damage and enhances chemotherapeutic response in prostate cancer cells.Medical oncology (Northwood, London, England) · 2023Article
- Landscape of NcRNAs involved in drug resistance of breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Down-regulation of DNA key protein-FEN1 inhibits OSCC growth by affecting immunosuppressive phenotypes via IFN-γ/JAK/STAT-1.International journal of oral science · 2023Article
- Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma.Cancers · 2021Article
- Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response.Progress in biophysics and molecular biology · 2021Article
- The Clinical Significance of the Expression of FEN1 in Primary Osteosarcoma.International journal of general medicine · 2021Article
- Identification of Key Genes Related to Lung Squamous Cell Carcinoma Using Bioinformatics Analysis.International journal of molecular sciences · 2020Article
- Cross-Species Complementation of Nonessential Yeast Genes Establishes Platforms for Testing Inhibitors of Human Proteins.Genetics · 2020Article
- Inhibition of FEN1 Increases Arsenic Trioxide-Induced ROS Accumulation and Cell Death: Novel Therapeutic Potential for Triple Negative Breast Cancer.Frontiers in oncology · 2020Article
- IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism.Frontiers in oncology · 2020Article
- FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells.Cancer medicine · 2019Article
- miR-193b Increases the Chemosensitivity of Osteosarcoma Cells by Promoting FEN1-Mediated Autophagy.OncoTargets and therapy · 2019Article
- Integrated Bioinformatics Analysis of Hub Genes and Pathways in Anaplastic Thyroid Carcinomas.International journal of endocrinology · 2019Article
Corrections and comments
- Erratum for
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.